RxDoctor Payments Data

Dava Helton, APRN

Family · Clarksville, INNPI 1649711698

Payments from drug & device makers

$1,130in general payments, 2019–2025

Across 44 payments — averaging $25.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$508
  • Lilly USA, LLC$170
  • AbbVie$142
  • Phathom Pharmaceuticals, Inc.$139
  • Biohaven Pharmaceutical Holding Company Ltd.$129
  • Cipher Pharmaceuticals US LLC$41

What the payments were for

  • Food & beverage$1,130100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk26$508
Lilly USA, LLC2$170
AbbVie4$142
Phathom Pharmaceuticals, Inc.4$139
Biohaven Pharmaceutical Holding Company Ltd.7$129
Cipher Pharmaceuticals US LLC1$41

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,130 in reported general payments places this provider in the 65th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$23,223
Medicare patients
95
Services billed
355

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide23$37,946
WegovySemaglutide21$33,507
JardianceEmpagliflozin11$20,070
TrulicityDulaglutide12$19,495
MounjaroTirzepatide12$18,627
Levothyroxine Sodium119$1,421
Albuterol Sulfate HfaAlbuterol Sulfate48$1,165
Atorvastatin Calcium140$989
Gabapentin45$878
Acyclovir13$676
Sertraline Hcl49$514
Losartan Potassium40$500
Pantoprazole Sodium30$445
Omeprazole39$405
Buspirone Hcl26$394

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$508$71,45244 claims
Lilly USA, LLCTrulicity, Mounjaro$170$38,12224 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,392 family providers in Indiana.

Other family in Clarksville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →